Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3VS
|
|||
| Former ID |
DIB013513
|
|||
| Drug Name |
Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes
|
|||
| Synonyms |
Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma); Autologous anti-gp100 TCR gene-engineered PBLs (melanoma), NCI; Autologous anti-gp100 T-cell receptor gene-engineered peripheral blood lymphocytes (melanoma), National Cancer Institute
Click to Show/Hide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Company |
National Cancer Institute
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00509496) Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.